drugset / Trial / NCT05897216
Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029
RandomizedCrossoverOpen-labelTreatment
Summary
Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D745, D150 and D029 for Healthy Subjects in Fed State
Timeline
- Start
- 2023-07-14
- Primary completion
- 2023-07-23
- Completion
- 2023-08-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CKD-383 | Unknown | — | Oral |
| Subject | D029 | Unknown | — | Oral |
| Subject | D150 | Unknown | — | Oral |
| Subject | D745 | Unknown | — | Oral |
| Subject | Lobeglitazone | Small molecule | — | Oral |